OXTR/OXYR recombinant proteins and antibodies

The oxytocin receptor (OXTR), also called OXYR is a classic G protein–coupled receptor (GPCR) encoded by the OXTR gene. It binds to the neuropeptide oxytocin (OXT) to mediate various physiological and behavioral effects. OXTR is highly expressed in uterine smooth muscle and mammary gland epithelial cells, where it regulates labor and lactation. In the central nervous system, it is distributed in the amygdala, hypothalamus, and nucleus accumbens, playing key roles in social bonding, emotional regulation, and stress adaptation. OXTR signaling primarily involves the Gq/11–phospholipase C pathway, leading to intracellular Ca²⁺ release and smooth muscle contraction or neuronal activation.

Historically, OXTR-targeted drugs were developed for obstetric and lactation purposes. The best-known example, Pitocin (oxytocin injection), is routinely used to induce labor. More recently, OXTR has gained attention as a neuropsychiatric drug target, with therapeutic potential for autism spectrum disorder (ASD), social anxiety, depression, and post-traumatic stress disorder (PTSD). Studies suggest that oxytocin and OXTR agonists can enhance social cognition and emotional regulation, making them promising candidates for neurobehavioral modulation.

Globally, Ferring Pharmaceuticals, Otsuka, Terapio, and NeuroRx are leading the development of OXTR-targeted drugs. Carbetocin, a long-acting oxytocin analog developed by Otsuka and Japan’s National Center of Neurology and Psychiatry, is approved for postpartum hemorrhage prevention and is being evaluated for ASD treatment. Companies such as Terapio and NeuroRx are developing small-molecule OXTR agonists and modulators to address social dysfunction and affective disorders. In China, research institutions have initiated OXTR ligand screening and signaling studies. In summary, the oxytocin receptor serves as a bridge between physiological and emotional regulation. Its therapeutic scope is expanding from traditional obstetric use to the treatment of psychiatric and social cognitive disorders, offering promising opportunities for innovative drug discovery.

To assist in the development of OXTR/OXYR-targeted small molecule drugs, DIMA BIOTECH can now provide full-length OXTR recombinant membrane protein developed by its nanodisc membrane protein platform. OXTR nanodisc is an optimal solution for screening small molecules targeting OXTR with its natural structure. Furthermore, DIMA BIOTECH has also prepared a OXTR single B cell seed library, from which lead antibody molecules can be obtained in as fast as 28 days.